In addition, hydroxylated analogs of 4-HB, 3,4-dihydroxybenzoic acid and/or vanillic acid were marked as a potential therapeutic intervention for CoQ10 deficiency due to a COQ6 mutation.131. The gene discussed is COQ6; the disease is coenzyme Q10 deficiency.